March 03, 2025

Omalizumab Bests Oral Immunotherapy for Food Allergies

"These differences were largely driven by the high rate of adverse events leading to study discontinuation in the OIT-treated participants, despite receiving omalizumab treatment at the initiation of therapy."

Conexiant

February 27, 2025

Can a Flexible Thrombectomy Device Clear Venous Clots?

A novel dumbbell-shaped thrombectomy device, called the Venus-TD, demonstrated high recanalization rates and favorable outcomes among patients with cerebral venous sinus thrombosis.

Conexiant

February 19, 2025

Late-Window Alteplase in Acute Ischemic Stroke

"We believe these findings mean more people may return to normal or near-normal lives after a stroke, even if they receive treatment later than originally thought beneficial."

Conexiant

February 18, 2025

Telomere Length May Signal Brain Disease Risk

Compared to those with longer telomeres, individuals with the shortest telomeres demonstrated an 8% higher risk of stroke, a 19% higher risk of dementia, and a 14% higher risk of late-life depression.

Conexiant

February 12, 2025

Can Skin Patches Ease Prostate Therapy?

A phase 2 trial presents promising findings on the effectiveness of transdermal estradiol patches in delivering part of the androgen deprivation therapy for prostate cancer patients, showing potential in reducing adverse effects.

Reuters

February 12, 2025

Obinutuzumab Boosts Lupus Nephritis Treatment Success

Phase 3 trial shows adding obinutuzumab to standard lupus nephritis therapy improved complete renal response rates by 13.4 percentage points over placebo, though serious infection risks increased.

Conexiant

February 10, 2025

Can Cats Transmit H5N1 to Humans?

Growing cases of domestic cats affected by bird flu, risking zoonotic transmission and public health. Vaccination, food safety, and risks related to cat behaviors are crucial.

KFF Health News

February 07, 2025

24-Month Study Shows Ritlecitinib Efficacy in Alopecia

73.5% of patients achieved a SALT score ≤ 20 after 24 months of ritlecitinib treatment, according to new phase III findings.

Conexiant

February 06, 2025

Pediatric Stroke Survivors Show Higher Mental Health Risks

New research reveals children who survive strokes face increased rates of anxiety, depression, and physical symptoms, with age 9 identified as a critical period for mental health challenges, according to findings presented at the 2025 International Stroke Conference.

Conexiant